AbbVievsBeta Bionics

ABBV and BBNX stock compared: price, dividend, valuation and results, from SEC filings.

BBNX

Beta Bionics, Inc.

$15.11

Value $821M

-0.69%
BBNX's page

AbbVie (ABBV) has a market value of $518B and Beta Bionics (BBNX) $821M. Over the last year, with dividends, ABBV moved +29.9% and BBNX -44.4%. Dividend yield: ABBV 2.36%, BBNX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$518B

    BBNX$821M

    ABBV is 631 times BBNX

  • Revenue, 12 months

    ABBV$66.0B

    BBNX$127M

    ABBV is 519 times BBNX

  • Net income, 12 months

    ABBV$10.3B

    BBNX-$83M

  • Operating margin

    ABBV32.2%

    BBNX-72.8%

    104.9 points apart

  • ROIC

    ABBV25.7%

    BBNX-24.2%

    49.9 points apart

  • P/E

    ABBV50.4

    BBNX–

  • Dividend yield

    ABBV2.4%

    BBNX0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+29.9%

BBNX-44.4%

50100DecFebAprJunAugOct
Returns by period
PeriodABBVWith dividendsBBNXWith dividends
1 year since November 14, 2025+29.9%Price +26.2%-44.4%Price -44.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieBBNXBeta Bionics

Valuation

ABBVBBNX
Valuation
Price$293.20$15.11
Market value$518B$821M
Enterprise value (EV)$589B$581M
P/E50.4–
P/E, 5-year median57.0–
P/B–2.1
EV/EBIT27.7–
Free cash flow yield3.6%–

Results and growth

ABBVBBNX
Results and growth
Revenue, 12 months$66.0B$127M
Net income, 12 months$10.3B-$83M
Free cash flow, 12 months$18.9B-$66M
Earnings per share, 12 months$5.81-$1.83
Revenue growth, year on year8.6%53.9%
Revenue growth a year, past+5.9%over 5 years+189.1%over 2 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVBBNX
Margins and returns on capital
Gross margin73.7%58.6%
Operating margin32.2%-72.8%
Net margin15.7%-65.3%
ROIC25.7%-24.2%
ROE–-27.5%

Balance sheet

ABBVBBNX
Balance sheet
Cash$10.8B$240M
Total debt$80.9B$6.2M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVBBNX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or BBNX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Beta Bionics?

By market value, AbbVie ($518B) is about 631.3 times Beta Bionics ($821M), at today's prices.

How did ABBV and BBNX stock do over the last 1 years?

Since November 14, 2025, ABBV's price moved +26.2% and BBNX's -44.4%. With dividends: ABBV +29.9% (+29.9% a year), BBNX -44.4% (-44.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or BBNX?

The dividend yield at today's price is 2.36% for AbbVie and none for Beta Bionics. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Beta Bionics?

Over the last twelve months, the net margin was 15.7% for AbbVie and -65.3% for Beta Bionics, and the operating margin 32.2% and -72.8%. Revenue was $66.0B and $127M.

Which is the better investment, AbbVie or Beta Bionics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.